Literature DB >> 2972942

Autoradiographic localization of D1 and D2 dopamine receptors in the human brain.

J De Keyser1, A Claeys, J P De Backer, G Ebinger, F Roels, G Vauquelin.   

Abstract

The distribution of dopamine D1 and D2 receptors in several human brain regions was investigated using autoradiography with the radioligands [3H]SCH 23390 and [3H]spiroperidol. The highest densities of both dopamine receptor types are seen in the nucleus caudatus, putamen and nucleus accumbens. Whereas the density of the D2 receptors is similar in the two segments of the globus pallidus, the pars medialis of the globus pallidus contains a three-fold higher concentration of D1 receptors than the pars lateralis. D1 and D2 receptors are present in the amygdala and substantia nigra. Both receptor types are absent in the cerebellum. The thalamus contains low densities of D1 receptors but no D2 receptors. Only D2 receptors are seen in the anterior lobe of the pituitary gland. The whole cerebral cortex is rich in D1 receptors, while D2 receptors, in low concentrations, are confined to the entorhinal area and cingulate cortex.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972942     DOI: 10.1016/0304-3940(88)90758-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  23 in total

1.  Age-related changes in human D1 dopamine receptors measured by positron emission tomography.

Authors:  T Suhara; H Fukuda; O Inoue; T Itoh; K Suzuki; T Yamasaki; Y Tateno
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 2.  Anticlockwise or clockwise? A dynamic Perception-Action-Laterality model for directionality bias in visuospatial functioning.

Authors:  A K M Rezaul Karim; Michael J Proulx; Lora T Likova
Journal:  Neurosci Biobehav Rev       Date:  2016-06-24       Impact factor: 8.989

Review 3.  The Gordon Wilson Lecture. Decade of the brain: advances and hopes at the midpoint.

Authors:  G S Oxford
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

4.  Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride.

Authors:  M S Lidow; P S Goldman-Rakic; P Rakic; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

5.  Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging.

Authors:  Simon Kaller; Michael Rullmann; Marianne Patt; Georg-Alexander Becker; Julia Luthardt; Johanna Girbardt; Philipp M Meyer; Peter Werner; Henryk Barthel; Anke Bresch; Thomas H Fritz; Swen Hesse; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-14       Impact factor: 9.236

Review 6.  Biochemical and behavioural properties of clozapine.

Authors:  D M Coward; A Imperato; S Urwyler; T G White
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 7.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

8.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

9.  Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.

Authors:  S Sarre; P Herregodts; D Deleu; A Devrieze; N De Klippel; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

10.  D1 dopamine receptor binding in mood disorders measured by positron emission tomography.

Authors:  T Suhara; K Nakayama; O Inoue; H Fukuda; M Shimizu; A Mori; Y Tateno
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.